Regeneron Pharmaceuticals anticipates recording an acquired in-process research and development (IPR&D) charge of approximately $24 million pre-tax for Q2 2024. This charge stems from up-front payments and premium payments on equity securities related to collaboration and licensing agreements.The IPR&D charge is expected to reduce both GAAP and non-GAAP net income per diluted share by approximately $0.18 for the second quarter. The company notes that these preliminary results are subject to financial statement closing procedures and actual results may differ from current estimates.

Regeneron Pharmaceuticals anticipates recording an acquired in-process research and development (IPR&D) charge of approximately $24 million pre-tax for Q2 2024. This charge stems from up-front payments and premium payments on equity securities related to collaboration and licensing agreements.The IPR&D charge is expected to reduce both GAAP and non-GAAP net income per diluted share by approximately $0.18 for the second quarter. The company notes that these preliminary results are subject to financial statement closing procedures and actual results may differ from current estimates.